Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by jicoopon May 30, 2022 7:49pm
231 Views
Post# 34718525

RE:RE:RE:RE:RE:88% demonstrate that CR at 180 days, 69% at 270 days

RE:RE:RE:RE:RE:88% demonstrate that CR at 180 days, 69% at 270 days

Heye gang, still hanging in here, did some travel in Europe recently for a spring break . 

Yes, agree with results being promising, but the point below needed to be clarified. thanks FGP .

Good news is that the Total of CR and PR at 360 is 39% , which is a healthy number . The possibilty exists for some of the PR group to become CR . See here :

3 Partial Response (“PR”) is defined as patients who display either positive cystoscopy and negative urine cytology or negative cystoscopy and positive urine cytology during an assessment visit. According to the FDA guidance, patients participating in Study II, who are currently diagnosed as PR, may be re-classified as CR, if the cystoscopy is positive, low grade NMIBC is detected and the urine cytology is negative or if urine cytology is positive, cystoscopy is negative and upper tract or prostatic urethra urothelial cell carcinoma is detected.

Coop

FGPstock wrote:

I think you guys may be reading this statement wrong. 46% were CR after 90 days. then 88% of the 46% were still CR after 180.

Not sure how the PR factors in


For all Evaluable Patients, who achieved a CR at 90 days88% demonstrate that CR at 180 days, 69% at 270 days, 50% at 360 days and 56% at 450 days, demonstrating a strong duration of complete response.


<< Previous
Bullboard Posts
Next >>